PDF(Pubmed)
Abstract：
To evaluate outcomes of European cross-border multidisciplinary tumor boards in terms of participation, adherence to treatment recommendations, and access to novel treatment strategies.
The European reference network for rare gynecological tumors (EURACAN G2 domain) aims to improve the diagnosis, management, and treatment of patients with these cancers. Cross-border multidisciplinary tumor boards were initiated to facilitate intercollegiate clinical discussions across Europe and increase patients\' access to specialist treatment recommendations and clinical trials. All G2 healthcare providers were invited to participate in monthly multidisciplinary meetings. Patient data were collected using a standardized form and case summaries were distributed before each meeting. After each tumor board, a meeting summary with treatment recommendations was sent to all participants and the project manager at the coordinating center. The multidisciplinary tumor board format and outcomes were regularly discussed at G2 domain meetings. Anonymized clinical data and treatment recommendations were registered in a prospective database. For this report, clinical data were collected between November 2017 and December 2020 and follow-up data retrieved until May 2021.
During the 3-year period, 31 multidisciplinary tumor boards were held with participants from 10 countries and 20 centers. 91 individual patients were discussed between one and six times for a total of 109 case discussions. Follow-up data were retrieved from 64 patients and 80 case discussions. Adherence to treatment recommendations was 99%. Multidisciplinary tumor board recommendations resulted in 11 patients getting access to off-label treatment and one patient being enrolled in a clinical trial in another European country. 14/91 patients were recommended for surveillance only when additional treatment had been considered locally.
Cross-border multidisciplinary tumor boards enable networking and clinical collaboration between healthcare professionals in different countries. Surveillance strategies, off-label drug use, and increased participation in clinical trials are possible benefits to patients with rare gynecological tumors.
The European reference network for rare gynecological tumors (EURACAN G2 domain) aims to improve the diagnosis, management, and treatment of patients with these cancers. Cross-border multidisciplinary tumor boards were initiated to facilitate intercollegiate clinical discussions across Europe and increase patients\' access to specialist treatment recommendations and clinical trials. All G2 healthcare providers were invited to participate in monthly multidisciplinary meetings. Patient data were collected using a standardized form and case summaries were distributed before each meeting. After each tumor board, a meeting summary with treatment recommendations was sent to all participants and the project manager at the coordinating center. The multidisciplinary tumor board format and outcomes were regularly discussed at G2 domain meetings. Anonymized clinical data and treatment recommendations were registered in a prospective database. For this report, clinical data were collected between November 2017 and December 2020 and follow-up data retrieved until May 2021.
During the 3-year period, 31 multidisciplinary tumor boards were held with participants from 10 countries and 20 centers. 91 individual patients were discussed between one and six times for a total of 109 case discussions. Follow-up data were retrieved from 64 patients and 80 case discussions. Adherence to treatment recommendations was 99%. Multidisciplinary tumor board recommendations resulted in 11 patients getting access to off-label treatment and one patient being enrolled in a clinical trial in another European country. 14/91 patients were recommended for surveillance only when additional treatment had been considered locally.
Cross-border multidisciplinary tumor boards enable networking and clinical collaboration between healthcare professionals in different countries. Surveillance strategies, off-label drug use, and increased participation in clinical trials are possible benefits to patients with rare gynecological tumors.
摘要：
目的：评估欧洲跨界多学科肿瘤委员会在参与方面的结果，坚持治疗建议，并获得新的治疗策略。
方法：欧洲罕见妇科肿瘤参考网络（EURACANG2域）旨在改善诊断，管理,以及这些癌症患者的治疗。跨境多学科肿瘤委员会启动，以促进欧洲的大学间临床讨论，并增加患者获得专科治疗建议和临床试验的机会。邀请所有G2医疗保健提供者参加每月的多学科会议。使用标准化表格收集患者数据，并在每次会议前分发病例摘要。在每个肿瘤板之后，向协调中心的所有参与者和项目经理发送了包含治疗建议的会议摘要。在G2域会议上定期讨论多学科肿瘤委员会的格式和结果。匿名的临床数据和治疗建议在前瞻性数据库中注册。对于这份报告，我们收集了2017年11月至2020年12月期间的临床数据,并检索到2021年5月之前的随访数据.
结果：在3年期间，举办了31个多学科肿瘤委员会，参与者来自10个国家和20个中心。91例患者共讨论了1至6次，共讨论了109例。随访数据来自64例患者和80例病例讨论。对治疗建议的依从性为99%。多学科肿瘤委员会的建议导致11名患者获得标签外治疗，一名患者在另一个欧洲国家参加临床试验。仅在考虑在当地进行额外治疗时，才建议对14/91患者进行监测。
结论：跨境多学科肿瘤委员会使不同国家的医疗保健专业人员之间能够联网和临床合作。监测战略,标签外药物使用，增加参与临床试验可能对罕见妇科肿瘤患者有益。
方法：欧洲罕见妇科肿瘤参考网络（EURACANG2域）旨在改善诊断，管理,以及这些癌症患者的治疗。跨境多学科肿瘤委员会启动，以促进欧洲的大学间临床讨论，并增加患者获得专科治疗建议和临床试验的机会。邀请所有G2医疗保健提供者参加每月的多学科会议。使用标准化表格收集患者数据，并在每次会议前分发病例摘要。在每个肿瘤板之后，向协调中心的所有参与者和项目经理发送了包含治疗建议的会议摘要。在G2域会议上定期讨论多学科肿瘤委员会的格式和结果。匿名的临床数据和治疗建议在前瞻性数据库中注册。对于这份报告，我们收集了2017年11月至2020年12月期间的临床数据,并检索到2021年5月之前的随访数据.
结果：在3年期间，举办了31个多学科肿瘤委员会，参与者来自10个国家和20个中心。91例患者共讨论了1至6次，共讨论了109例。随访数据来自64例患者和80例病例讨论。对治疗建议的依从性为99%。多学科肿瘤委员会的建议导致11名患者获得标签外治疗，一名患者在另一个欧洲国家参加临床试验。仅在考虑在当地进行额外治疗时，才建议对14/91患者进行监测。
结论：跨境多学科肿瘤委员会使不同国家的医疗保健专业人员之间能够联网和临床合作。监测战略,标签外药物使用，增加参与临床试验可能对罕见妇科肿瘤患者有益。
